Home › NDC Lookup › RxCUI directory › RxCUI 2200291

Nabumetone 1000 MG Oral Tablet [Relafen] — RxCUI 2200291

RxNorm drug concept · Semantic branded drug
RxCUI 2200291 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2200291
Official nameNabumetone 1000 MG Oral Tablet [Relafen]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRelafen 1000 MG Oral Tablet; Relafen DS 1000 MG Oral Tablet
FDA products mapped1
Package NDCs mapped4
Reported Medicaid activity (SDUD)18,048 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Nabumetone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Nabumetone is a prescription anti-inflammatory medication used to ease the pain, swelling, and stiffness that come with osteoarthritis and rheumatoid arthritis. It won't cure arthr...
  • Yes, you can take it with or without food — both are fine. Taking it with food or milk does speed up how quickly it gets into your system, so if you want faster relief, with a meal...
  • Can I take nabumetone with food? Does it matter?
  • The most common ones are digestive — things like diarrhea, indigestion, and stomach pain. Those are bothersome but usually manageable. What you really want to watch out for are bla...
📖 Read our full Nabumetone guide →

🕸️ Concept Web — How Nabumetone 1000 MG Oral Tablet [Relafen] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Nabumetone 1000 MG Oral Tablet [Relafen] RxCUI 2200291

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Nabumetone 31448
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Relafen 203754
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Nabumetone Oral Tablet 378684
    • Nabumetone Oral Product 1158379
    • Nabumetone Pill 1158380
    • Nabumetone Oral Tablet [Relafen] 368811
    • Relafen Oral Product 1180091
    • Relafen Pill 1180092
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Nabumetone 1000 MG Oral Tablet SCD · 427726
  • Nabumetone 1000 MG SCDC · 446597
  • Nabumetone Oral Tablet SCDF · 378684
  • Nabumetone Oral Product SCDG · 1158379
  • Nabumetone Pill SCDG · 1158380

Brand-Name Concepts

  • Nabumetone 1000 MG [Relafen] SBDC · 2200290
  • Nabumetone Oral Tablet [Relafen] SBDF · 368811
  • Relafen Oral Product SBDG · 1180091
  • Relafen Pill SBDG · 1180092
  • Relafen BN · 203754

📦 FDA Products & Package NDCs

1 product · 4 package NDCs
4 package NDCs map to RxCUI 2200291 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
15370-0170-10 100 TABLET in 1 BOTTLE, PLASTIC (15370-170-10) RELAFEN DS Carwin Pharmaceutical Associates, LLC 2022-05-12
15370-0170-30 30 TABLET in 1 BOTTLE, PLASTIC (15370-170-30) RELAFEN DS Carwin Pharmaceutical Associates, LLC 2019-09-20
15370-0170-60 60 TABLET in 1 BOTTLE, PLASTIC (15370-170-60) RELAFEN DS Carwin Pharmaceutical Associates, LLC 2020-02-28
15370-0170-99 1 BLISTER PACK in 1 CARTON (15370-170-99) / 2 TABLET in 1 B... RELAFEN DS Carwin Pharmaceutical Associates, LLC 2020-02-28
Observed labelers: Carwin Pharmaceutical Associates, LLC (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$31.6667
Range $31.6667–$31.6667 · middle 50% $31.6667–$31.6667 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.